Clinical evaluation of pirozadil, administered continuously over four and a half years, in patients with hyperlipoproteinemia type IIa
Evaluación clínica del pirozadil administrado ininterrumpidamente durante 4.5 años a pacientes con hiperlipoproteinemia tipo IIa